Patents by Inventor Maurits KLEIJNEN

Maurits KLEIJNEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptides
    Publication number: 20230346885
    Abstract: The present invention relates to novel peptides derived from various target proteins, complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
    Type: Application
    Filed: December 9, 2022
    Publication date: November 2, 2023
    Inventors: Alex Powlesland, Alfred Lim, Alina Popa, Andrew Brooks, Benjamin Oestringer, Chandramouli Reddy Chillakuri, Christopher Sayer, Dhaval Jaykant Sangani, Elena Galfre, Fiona Chester, Garret Keating, Graham Anthony Hood, Izabela Bombik, Johanne Pentier, Maurits Kleijnen, Meidai Sun, Nicole Mai, Philip Addis, Pietro Dellacristina, Sarah Gilgunn, Victoria Arena De Souza
  • PEPTIDES DERIVED FROM TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL SUBFAMILY M MEMBER 1 (TRPM1), COMPLEXES COMPRISING SUCH PEPTIDES BOUND TO MHC MOLECULES
    Publication number: 20220175949
    Abstract: The present invention relates to novel peptides derived from Transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
    Type: Application
    Filed: August 7, 2020
    Publication date: June 9, 2022
    Inventors: Alex POWLESLAND, Maurits KLEIJNEN, Meidai SUN
  • PEPTIDES
    Publication number: 20210139558
    Abstract: Peptides derived from 5-hydroxytryptamine receptor 3A (HTR3A), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules are described. Also provided are binding moieties that bind to the peptides and/or complexes described. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
    Type: Application
    Filed: November 25, 2020
    Publication date: May 13, 2021
    Inventors: Alex POWLESLAND, Maurits KLEIJNEN
  • PEPTIDES DERIVED FROM SOLUTE CARRIER FAMILY 45 MEMBER 2 (SLC45A2) AND USES THEREOF
    Publication number: 20210122784
    Abstract: The present invention relates to novel peptides derived from solute carrier family 45 member 2 (SLC45A2), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
    Type: Application
    Filed: November 9, 2020
    Publication date: April 29, 2021
    Inventors: Alex POWLESLAND, Meidai SUN, Maurits KLEIJNEN
  • PEPTIDES
    Publication number: 20210122803
    Abstract: The present invention relates to novel peptides derived from Structural maintenance of chromosomes protein 1B (SMC1B), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
    Type: Application
    Filed: November 16, 2020
    Publication date: April 29, 2021
    Inventors: Alex POWLESLAND, Meidai SUN, Maurits KLEIJNEN
  • PEPTIDES DERIVED FROM LENGSIN (LGSN), COMPLEXES COMPRISING SUCH PEPTIDES BOUND TO MHC MOLECULES
    Publication number: 20210123037
    Abstract: The present invention relates to novel peptides derived from Lengsin (LGSN), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
    Type: Application
    Filed: October 28, 2020
    Publication date: April 29, 2021
    Inventors: Alex POWLESLAND, Maurits KLEIJNEN
  • Peptides derived from transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to MHC molecules
    Patent number: 10980893
    Abstract: The present invention relates to novel peptides derived from Transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: April 20, 2021
    Assignee: IMMUNOCORE LIMITED
    Inventors: Alex Powlesland, Maurits Kleijnen, Meidai Sun
  • PEPTIDES DERIVED FROM TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL SUBFAMILY M MEMBER 1 (TRPM1), COMPLEXES COMPRISING SUCH PEPTIDES BOUND TO MHC MOLECULES
    Publication number: 20210093732
    Abstract: The present invention relates to novel peptides derived from Transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
    Type: Application
    Filed: August 7, 2020
    Publication date: April 1, 2021
    Inventors: Alex POWLESLAND, Maurits KLEIJNEN, Meidai SUN
  • Peptides derived from transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to MHC molecules
    Patent number: 10946105
    Abstract: The present invention relates to novel peptides derived from Transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: March 16, 2021
    Assignee: IMMUNOCORE LIMITED
    Inventors: Alex Powlesland, Maurits Kleijnen, Meidai Sun
  • Peptides derived from Lengsin (LGSN), complexes comprising such peptides bound to MHC molecules
    Patent number: 10851366
    Abstract: The present invention relates to novel peptides derived from Lengsin (LGSN), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: December 1, 2020
    Assignee: IMMUNOCORE LIMITED
    Inventors: Alex Powlesland, Maurits Kleijnen
  • PEPTIDES
    Publication number: 20180346517
    Abstract: The present invention relates to novel peptides derived from solute carrier family 45 member 2 (SLC45A2), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
    Type: Application
    Filed: November 23, 2016
    Publication date: December 6, 2018
    Inventors: Alex POWLESLAND, Meidai SUN, Maurits KLEIJNEN
  • PEPTIDES
    Publication number: 20180346545
    Abstract: The present invention relates to novel peptides derived from 5-hydroxytryptamine receptor 3A (HTR3A), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
    Type: Application
    Filed: November 23, 2016
    Publication date: December 6, 2018
    Inventors: Alex POWLESLAND, Maurits KLEIJNEN
  • PEPTIDES DERIVED FROM TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL SUBFAMILY M MEMBER 1 (TRPM1), COMPLEXES COMPRISING SUCH PEPTIDES BOUND TO MHC MOLECULES
    Publication number: 20180344867
    Abstract: The present invention relates to novel peptides derived from Transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
    Type: Application
    Filed: November 23, 2016
    Publication date: December 6, 2018
    Inventors: Alex POWLESLAND, Maurits KLEIJNEN, Meidai SUN
  • PEPTIDES
    Publication number: 20180340018
    Abstract: The present invention relates to novel peptides derived from Structural maintenance of chromosomes protein 1 B (SMC1 B), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
    Type: Application
    Filed: November 23, 2016
    Publication date: November 29, 2018
    Inventors: Alex POWLESLAND, Meidai SUN, Maurits KLEIJNEN
  • PEPTIDES DERIVED FROM LENGSIN (LGSN), COMPLEXES COMPRISING SUCH PEPTIDES BOUND TO MHC MOLECULES
    Publication number: 20180327736
    Abstract: The present invention relates to novel peptides derived from Lengsin (LGSN), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
    Type: Application
    Filed: November 23, 2016
    Publication date: November 15, 2018
    Inventors: Alex POWLESLAND, Maurits KLEIJNEN